TRINETRA › Sectors › Healthcare
Syngene International Limited (SYNGENE) — share price, P/E and fundamentals
Syngene International Limited (NSE: SYNGENE) closed at ₹402.70 on 30 Oct 2026, -36.9% over one year, against a 52-week range of ₹344.45 – ₹678.95.
In the quarter ended 30 Sept 2026 (consolidated, filed 27 Oct 2026) it reported revenue of ₹833 cr and net profit of ₹32 cr, a 3.9% net margin; revenue fell 8.6% and profit fell 44.8% year on year.
On four consecutive filed quarters its trailing P/E is 87.4; since 24 Apr 2025 its own P/E has ranged from 44.5 to 87.0 (median 52.9), and today's reading is higher than 100% of those 375 trading days.
From the balance sheet dated 30 Sept 2026: return on equity 2.7%, ROCE 4.2%, debt-to-equity 0.01, Piotroski F-score 4 of 9.
Against 65 Healthcare peers on NSE: Net margin higher than 13% of 63 sector peers; PBT margin higher than 11% of 63 sector peers; ROE higher than 10% of 63 sector peers.
Key figures
| Last close | ₹402.70 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | +5.9% / -4.4% / -36.9% |
| 52-week low – high | ₹344.45 – ₹678.95 |
| Market capitalisation | ₹16,257 cr |
| Trailing P/E | 87.4 |
| Price / book | 3.35 |
| EV / EBITDA | 21.8 |
| Earnings yield | 1.1% |
| TTM EPS | ₹4.61 |
| TTM net profit | ₹186 cr |
| Quarter revenue | ₹833 cr |
| Quarter net profit | ₹32 cr |
| Net margin | 3.9% |
| Revenue growth (YoY) | -8.6% |
| Profit growth (YoY) | -44.8% |
| Return on equity | 2.7% |
| ROCE | 4.2% |
| Debt / equity | 0.01 |
| Current ratio | 1.65 |
| Free cash flow | ₹-353 cr |
| Piotroski F-score | 4 / 9 |
| Average daily turnover (50 days) | ₹16.4 cr |
Against Healthcare peers
| Metric | SYNGENE | Peer median | Percentile |
|---|---|---|---|
| Net margin | 3.87 | 12.89 | 13 |
| PBT margin | 5.64 | 17.68 | 11 |
| ROE | 2.65 | 13.87 | 10 |
| ROCE | 4.16 | 17.26 | 6 |
| Debt / equity | 0.01 | 0.11 | 28 |
| FCF margin | -22.51 | 2.08 | 7 |
| Cash conversion | -6.17 | 1.25 | 0 |
| Trailing P/E | 87.36 | 43.07 | 92 |
Questions
What is the P/E ratio of Syngene International Limited?
Syngene International Limited's trailing P/E is 87.4, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Sept 2026. Since 24 Apr 2025 its P/E has ranged 44.5–87.0.
What were Syngene International Limited's latest quarterly results?
For the quarter ended 30 Sept 2026, Syngene International Limited reported revenue of ₹833 cr and net profit of ₹32 cr (consolidated), filed with the exchange on 27 Oct 2026.
What is Syngene International Limited's ROE?
Return on equity is 2.7% based on the balance sheet dated 30 Sept 2026.
Does Syngene International Limited have debt?
Debt-to-equity is 0.01 on the balance sheet dated 30 Sept 2026.
What is SYNGENE's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, SYNGENE traded between ₹344.45 and ₹678.95.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Sept 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.